Concurrently, the CD8 Tem (non: 22%, early: 34%, advanced: 45%) and CTLs (non: 21%, early: 51%, advanced: 62%) were observed to have lower risk frequencies in non-tumor and eHCC, compared with aHCC (Figure 5F). This evidence concerns the gene CD8A and neoplasm.